Insurer stocks fall after Trump says 'we're going to knock out the middleman'
Dec 16 (Reuters) -Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.
CVS Health's CVS.N Caremark, Cigna's CI.N Express Scripts and UnitedHealth Group's UNH.N Optum control the majority of the U.S. pharmacy benefit market, with their parent companies also operating health insurance and pharmacy businesses.
Pharmacy benefit managers negotiate drug costs with pharmacies and drug manufacturers and help build drug coverage lists for health plans, mostly on behalf of employers and the government. They directly reimburse pharmacies for prescription drugs included under their agreed terms.
"The horrible middleman that makes more money, frankly, than the drug companies, and they don't do anything except they're a middleman," Trump said on Monday, at a news conference at his Mar-a-Lago club in Palm Beach, Florida.
"I don't know who these middlemen are, but they are rich," he said.
Referring to his dinner earlier this month with key executives of drugmakers Pfizer PFE.N and Eli Lilly LLY.N, as well as industry lobbying group PhRMA, Trump said he spent much of it talking about the high costs of drugs and how the U.S. pays much more than other countries.
"We're going to knock out the middleman. We're going to get drug costs down at levels that nobody has ever seen before," Trump said.
Shares of CVS fell 5.35% to $46.73, Cigna slipped 2.6% to $274.63, while UnitedHealth was down 3.54% at $502.07 in afternoon trading.
"CVS leverages free-market competition to fight back against pharma price gouging, and we are proud of our continued work to make prescription drugs more affordable in the United States," a spokesperson for CVS said, adding that the company welcomes outreach from federal and state officials to discuss its value.
"Any policy that limits the use of (pharmacy benefit manager) negotiating tools would leave American patients, taxpayers, and businesses at the mercy of the prices drugmakers set."
ExpressScripts and Optum were not immediately available for comment.
Pharmacy benefit managers came under a House Oversight Committee investigation for their influence over prescription drug prices.
The Federal Trade Commission launched a suit in September, accusing Caremark, Optum and Express Scripts of artificially increasing their profit by unfairly limiting access to cheaper insulin drugs and steering patients toward more expensive options.
Reporting by Sriparna Roy in Bengaluru and Amina Niasse in New York; editing by Caroline Humer and Pooja Desai
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
